Orthocell Announces First US Remplir Sales Revenue
Filed with ASX · · 2 pages · English
Earlier from Orthocell
- Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ
- First Surgical Use of Remplir in US$1.6 Billion US Market
- Compelling Data Highlights Remplir Competitive Advantage
- Remplir Approved to Commence Sales in the Hong Kong Market
- 12 Distributors Signed for Remplir Covering 21 States in US
Later from Orthocell
- Appendix 4E & Annual Report
- Compelling 81% Success Rate for Remplir
- Remplir™ Study Delivers Compelling 81% Success Rate
- Remplir Use in Prostate Surgery Signals Global Opportunity
- Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery
Follow Orthocell into a list and get an email when it puts out news.
Follow Orthocell